Oruka Therapeutics, Inc. Payments to Acquire Marketable Securities
Oruka Therapeutics, Inc. (ORKA) reported Payments to Acquire Marketable Securities of $581.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Oruka Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $490.55M, a 354.21% increase year-over-year.
- Oruka Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $90.83M, a 105.09% increase year-over-year.
- Oruka Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $100.99M.
- Oruka Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $267.68M.
- Oruka Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $520.96M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 11 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $490.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $581.38M 10-Q · filed 2026-08-10 | $682.37M derived: sum of 3 quarters · filed 2026-08-10 | $950.05M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $90.83M 10-Q · filed 2026-05-13 | $191.82M derived: sum of 2 quarters · filed 2026-05-13 | $459.50M derived: sum of 3 quarters · filed 2026-05-13 | $567.50M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $100.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $368.67M derived: sum of 2 quarters · filed 2026-03-12 | $476.67M derived: sum of 3 quarters · filed 2026-08-10 | $520.96M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $267.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $375.68M derived: sum of 2 quarters · filed 2026-08-10 | $419.97M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $108.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $152.29M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $44.29M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | $329.94M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |